Sutro Biopharma (STRO) Receivables (2017 - 2025)

Sutro Biopharma has disclosed Receivables across 9 years of filings, most recently posting $4.0 million for Q4 2025.

• Receivables for Q4 2025 came in at $4.0 million, down 53.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.0 million (down 53.84% YoY), and the FY2025 annual result was $4.0 million, down 53.84% from the prior year.
• Receivables came in at $4.0 million for Q4 2025 at Sutro Biopharma, up from $3.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $97.7 million in Q2 2022 to a low of $3.9 million in Q3 2025.
• The 5-year median for Receivables is $9.9 million (2023), against an average of $16.2 million.
• Across the five-year window, Receivables jumped 966.28% in 2022 and slumped 89.76% in 2023, its largest moves.
• Sutro Biopharma's Receivables stood at $12.5 million in 2021, then slumped by 42.81% to $7.1 million in 2022, then soared by 406.57% to $36.1 million in 2023, then sank by 76.12% to $8.6 million in 2024, then plunged by 53.84% to $4.0 million in 2025.
• The last three Receivables figures came in at $4.0 million (Q4 2025), $3.9 million (Q3 2025), and $8.0 million (Q2 2025), per Business Quant data.